Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial
The PEARL Pilot is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
- Status
- active
- Phase
- Phase 2
- Institution
- University Health Network, Toronto
- Principal investigator
- Sarah Hales, MD
- Start date
- 2024-06-06
- End date
- 2026-12-15
- Registry ID
- NCT06416085
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.